ELUTIA INC. Faces Nasdaq Delisting Threat Due to Multiple Listing Rule Violations
ELUT sits 46% above its 52-week low of $0.5 on elevated volume (2.9× avg).
Summary
Elutia Inc. received a Nasdaq notice for failing to meet the minimum market value of listed securities, adding to its existing non-compliance with the minimum bid price rule and other financial standards, significantly increasing delisting risk.
Key Events · Corporate Governance and Compliance · ELUT
-
Nasdaq MVLS Non-Compliance
Elutia Inc. received a notice from Nasdaq for failing to maintain a $35 million minimum market value of listed securities (MVLS) for 30 consecutive business days.
-
Additional Financial Deficiencies
The notice also indicated that the company does not meet Nasdaq's minimum shareholder equity or net income standards.
-
Existing Bid Price Non-Compliance
The company remains non-compliant with the $1.00 minimum bid price rule, a deficiency previously disclosed on November 7, 2025.
-
Compliance Deadlines
Elutia has until June 22, 2026, to regain compliance with the MVLS requirement and until May 6, 2026, for the bid price rule.
Analysis · ELUT · Life Sciences
Elutia Inc. is facing severe challenges to maintain its Nasdaq listing, having received a notice for failing to meet the $35 million minimum market value of listed securities (MVLS) requirement. This new deficiency compounds an existing non-compliance with the $1.00 minimum bid price rule. The company also fails to meet minimum shareholder equity or net income standards, indicating broader financial distress. While there are compliance periods, the multiple and significant nature of these violations, coupled with the company's current market cap and stock price, suggest a high probability of delisting if a substantial turnaround or reverse stock split is not executed. Delisting would severely impact the stock's liquidity and investor confidence.
At the time of this filing, ELUT was trading at $0.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.6M. The 52-week trading range was $0.50 to $3.99. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.